Maximilian Doebler Appointed Chief Business Officer of HMNC Brain Health
MUNICH, Germany, Aug. 22, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage precision psychiatry...
Healthcare
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Medical Device Association Launches Hub for Research, Standards, News: AAMI ARRAY
ARLINGTON, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has launched a...
LifeMD and Cleared Offer New Hope to Allergy Patients Through Strategic Partnership With Allergenis
Strategic partnership enables direct-to-consumer food allergy clinic to provide convenient access to crucial peanut allergy threshold informationNEW YORK, Aug. 22,...
Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.
LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year...
Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema,...
Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to...
Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development
SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision...
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan...
Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery
Signs Definitive Agreement to Acquire Standard BariatricsWAYNE, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading...
InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Signs Five New Contracts, Adding more than 10,000 New Patients to its iUGO Care Platform
VANCOUVER, British Columbia, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Europe’s Leading Psychedelic Conference Launches Livestream Ticket Sales
The OPEN Foundation adds virtual access and invites attendance to ICPR 2022, the Interdisciplinary Conference on Psychedelic Research this September,...
P3 Health Partners Announces Receipt of Nasdaq Notice Regarding Late Filing of Periodic Report
HENDERSON, Nev., Aug. 19, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered...
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Kymera Announces $150 Million Private Placement Equity Financing
WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated...
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful...
CloudMD to Report Second Quarter Financial Results on Monday, August 22, 2022
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference
Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET /...